Quinupristin/Dalfopristin-induced Sweet's Syndrome.
- Author:
Hye Sook CHOI
1
;
Hee Jin KIM
;
Tae Hee LEE
;
Sang Hoon LEE
;
Tae Won LEE
;
Chun Gyoo IHM
;
Myung Jae KIM
Author Information
1. Department of Internal Medicine, School of Medicine, Kyung Hee University, Seoul, Korea. maxymus72@hanmail.net
- Publication Type:Case Report
- Keywords:
Sweet's syndrome;
Quinupristin/Dalfopristin (Streptogramins)
- MeSH:
Anti-Bacterial Agents/administration & dosage/*adverse effects;
Female;
Human;
Middle Aged;
Skin/drug effects/pathology;
Sweet's Syndrome/*chemically induced/pathology;
Virginiamycin/administration & dosage/*adverse effects/*analogs & derivatives
- From:The Korean Journal of Internal Medicine
2003;18(3):187-190
- CountryRepublic of Korea
- Language:English
-
Abstract:
Quinupristin/Dalfopristin is a new combination of streptogramin antibiotics designed specifically to treat clinically significant infections due to Vancomycin-resistant Enterococcus Faecium. Sweet's syndrome is characterized by painful skin plaques, which is associated with dermal neutrophilic infiltration, fever and peripheral blood leukocytosis. Drug-induced Sweet's syndrome has a temporal relationship between drug ingestion, clinical presentation and the temporally-related resolution of lesions following drug withdrawal or on treatment with systemic corticosteroids. A 63-year-old woman received Quinupristin/Dalfopristin for acute pyelonephritis developed fever, arthralgia, vomiting, and painful erythematous skin plaques. A skin biopsy showed neutrophilic dermatosis, and there was rapid resolution of the symptoms and cutaneous lesions after discontinuation of Quinupristin/Dalfopristin, consistent with drug-induced Sweet's syndrome. To date, there has been no reported case of Sweet's syndrome associated with the use of Quinupristin/Dalfopristin.
